Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab, anlotinib, and chemotherapy in stage III NSCLC
NCT04762030Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2021
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Started Feb 2021; status: recruiting.
02
Drugs
durvalumabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04762030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762030.